Recursion Pharmaceuticals (NASDAQ:RXRX) Sets New 1-Year Low After Analyst Downgrade

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday after JPMorgan Chase & Co. lowered their price target on the stock from $10.00 to $7.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Recursion Pharmaceuticals traded as low as $2.73 and last traded at $2.7050, with a volume of 8,315,663 shares changing hands. The stock had previously closed at $2.90.

Other research analysts also recently issued reports about the company. Morgan Stanley set a $5.90 price target on Recursion Pharmaceuticals in a report on Friday, October 16th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $7.58.

View Our Latest Report on RXRX

Insider Transactions at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 22,408 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the transaction, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total value of $155,200.00. Following the sale, the director directly owned 6,068,287 shares of the company’s stock, valued at $23,544,953.56. This trade represents a 0.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 167,408 shares of company stock worth $701,276. Company insiders own 6.65% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in RXRX. First Trust Advisors LP lifted its position in Recursion Pharmaceuticals by 16.8% during the third quarter. First Trust Advisors LP now owns 3,551,885 shares of the company’s stock valued at $14,669,000 after purchasing an additional 510,056 shares during the period. Jump Financial LLC raised its stake in shares of Recursion Pharmaceuticals by 145.0% during the 3rd quarter. Jump Financial LLC now owns 2,497,200 shares of the company’s stock valued at $10,313,000 after buying an additional 1,478,027 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after buying an additional 384,486 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $7,370,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after buying an additional 331,048 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Down 8.4%

The stock has a market cap of $1.65 billion, a PE ratio of -2.95 and a beta of 1.15. The business has a 50 day moving average price of $3.76 and a 200 day moving average price of $3.48.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.22). The company had revenue of $18.55 million during the quarter, compared to the consensus estimate of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. During the same period in the previous year, the company posted ($0.36) earnings per share. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

Featured Stories

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.